{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:26:14Z","timestamp":1788909974619,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.msard.2014.04.003","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T05:01:59Z","timestamp":1397365319000},"page":"520-526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients"],"prefix":"10.1016","volume":"3","author":[{"given":"Francesca","family":"Sangalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Barcella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaemma","family":"Rodegher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Martinelli Boneschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.msard.2014.04.003_bib1","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.msard.2014.04.003_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1468-1331.2011.03577.x","article-title":"Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study","volume":"19","author":"Borriello","year":"2012","journal-title":"Eur J Neurol"},{"issue":"16","key":"10.1016\/j.msard.2014.04.003_bib3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJM200304173481614","article-title":"Natalizumab for relapsing multiple sclerosis","volume":"348","author":"Chaudhuri","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.msard.2014.04.003_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2014.04.003_bib5","unstructured":"Cohen M, Maillart E, Papeix C, Vukusic S, Brassat D. ENIGM: a French observational study about switching from natalizumab to fingolimod in multiple sclerosis AAN; 2013, S41.002."},{"key":"10.1016\/j.msard.2014.04.003_bib6","doi-asserted-by":"crossref","unstructured":"Comi G, Gold R, Dahlke F, Sinha A, von Rosenstiel P., et al. Relapse outcomes in fingolimod-treated patients previously exposed to natalizumab: post-hoc analysis from the 4-month, open-label FIRST study. AAN; 2013, P07.103.","DOI":"10.1212\/WNL.80.7_supplement.P07.103"},{"issue":"9","key":"10.1016\/j.msard.2014.04.003_bib7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00415-011-5996-y","article-title":"De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate","volume":"258","author":"Havla","year":"2011","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.msard.2014.04.003_bib8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1352458510389103","article-title":"Course of relapsing-remitting multiple sclerosis before, during and after natalizumab","volume":"17","author":"Kaufman","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2014.04.003_bib9","unstructured":"Kaufman M, Cree B, De Seze J., et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study. ENS; 2012, O262."},{"issue":"1\u20132","key":"10.1016\/j.msard.2014.04.003_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jns.2011.05.043","article-title":"Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients","volume":"308","author":"Kerbrat","year":"2011","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.msard.2014.04.003_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ana.22074","article-title":"Natalizumab drug holiday in multiple sclerosis: poorly tolerated","volume":"68","author":"Killestein","year":"2010","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.msard.2014.04.003_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.msard.2014.04.003_bib14","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O\u2019Connor","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.04.003_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1331.2008.02517.x","article-title":"Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study","volume":"16","author":"Oturai","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.msard.2014.04.003_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1468-1331.2009.02728.x","article-title":"Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries","volume":"17","author":"Putzki","year":"2010","journal-title":"Eur J Neurol"},{"issue":"11","key":"10.1016\/j.msard.2014.04.003_bib17","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1352458512464282","article-title":"Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings","volume":"18","author":"Rinaldi","year":"2012","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.msard.2014.04.003_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"Sorensen","year":"2012","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.msard.2014.04.003_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1212\/01.wnl.0000327341.89587.76","article-title":"Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy","volume":"72","author":"St\u00fcve","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2014.04.003_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in Multiple Sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann Neurol"},{"issue":"13 Pt 2","key":"10.1016\/j.msard.2014.04.003_bib21","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034814000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034814000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:37:06Z","timestamp":1761899826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034814000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S2211034814000364"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2014.04.003","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2014.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}